**Table 3: Test performance according to clinical pathway.** Studies focusing on truly incidentally discovered adrenal masses (incidentaloma pathway) vs. studies on adrenal masses discovered during follow-up monitoring for extra-adrenal malignancy (follow-up from previous malignancy pathway).

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Incidentaloma pathway** | **>= 50% with incidentaloma** | | | **>= 90% with incidentaloma** | | | |
|  | **Studies (n/N)** | **Sensitivity (95%CI)** | **Specificity (95%CI)** | **Studies (n/N)** | **Sensitivity (95%CI)** | | **Specificity (95%CI)** |
| CT non–contrast tumor density (>10HU) | 2 (41/102) | 100% (91%-100%) | 72% (60% to 82%) | 1 (13/52) | 100% (75%-100%) | | 72% (55%-85%) |
| CT contrast enhanced washout (combination at 10 mins) | 1 (14/25) | 93% (68%-100%) | 100% (69%-100%) | 0 | - | | - |
| CT contrast enhanced washout (combination at 15 mins) | 1 (13/25) | 100% (75%-100%) | 92% (62%-100%) | 0 | - | |  |
| MRI adrenal-liver ratio (1.5 tesla only) | 1 (8/26) | 100% (63%-100%) | 44% (22%-69%) | 0 | - | | - |
| MRI adrenal-spleen ratio (1.5 tesla only) | 1 (12/49) | 58% (28%-85%) | 86% (71%-95%) | 0 | - | | - |
| MRI loss of signal intensity (1.5 tesla only) | 2 (20/75) | 86% (31%-99%) | 85% (73%-93%) | 0 | - | | - |
| PET ALR SUVmax | 2 (15/64) | 100% (78%-100%) | 96% (57%-100%) | 1 (12/41) | 100% (74%-100%) | | 100% (88%-100%) |
| PET SUVmax | 2 (15/64) | 93% (65%-99%) | 73% (59%-84%) | 1 (12/41) | 92% (62%-100%) | | 72% (53%-87%) |
| **Follow-up from previous malignancy pathway** | **>= 50% with current or prior non-adrenal malignancy** | | | **>= 90% with current or prior non-adrenal malignancy** | | | |
|  | **Studies (n/N)** | **Sensitivity** | **Specificity** | **Studies (n/N)** | | **Sensitivity** | **Specificity** |
| CT non–contrast tumor density (>10HU) | 5 (93/168) | 93% (79%-98%) | 71% (38%-91%) | 5 (93/168) | | 93% (79%-98%) | 71% (38%-91%) |
| CT contrast enhanced washout (absolute at 15 mins) | 1 (19/40) | 16% (3%-40%) | 86% (64%-97%) | 1 (19/40) | | 16% (3%-40%) | 86% (64%-97%) |
| CT contrast enhanced washout (relative at 15 mins) | 1 (19/40) | 16% (3%-40%) | 95% (76%-100%) | 1 (19/40) | | 16% (3%-40%) | 95% (76%-100%) |
| MRI adrenal-liver ratio (1.5 Tesla only) | 3 (37/129) | 89% (74%-96%) | 60% (21%-89%) | 2 (27/93) | | 92% (55%-99%) | 39% (21%-60%) |
| MRI adrenal-spleen ratio (1.5 Tesla only) | 3 (52/142) | 99% (69%-100%) | 84% (72%-91%) | 2 (42/105) | | 100% (92%-100%) | 79% (68%-88%) |
| MRI adrenal-muscle ratio (1.5 Tesla only) | 1 (10/37) | 90% (55%-100%) | 93% (76%-99%) | 0 | | - | - |
| MRI loss of signal intensity (1.5 Tesla only) | 1 (10/37) | 90% (55%-100%) | 85% (66%-96%) | 0 | | - | - |
| PET ALR SUVmax | 2 (45/117) | 82% (41%-97%) | 96% (76%-99%) | 1 (34/102) | | 94% (80%-99%) | 94% (86%-98%) |
| PET SUVmax | 3 (72/156) | 84% (62%-94%) | 90% (71%-97%) | 2 (61/141) | | 90% (80%-96%) | 87% (78%-93%) |

ALR SUVmax – ratio of SUVmax in the adrenal gland compared to the liver; CI – confidence interval; CT – computed tomography; HU – Hounsfield units; MRI – magnetic resonance imaging; n – number of cases; N – total population; PET – positron emission tomography; SUVmax - maximum standardized uptake value.